Thrivelab’s public information gives a reader several different views of progesterone: a menopause consultation, a broad hormone-care FAQ and a long medication price list. They are useful together, but they do not amount to a dispensing label. A capsule name in a table leaves questions that a general promise of personalized care cannot answer.
Reviewed September 29, 2026, this assessment follows those questions from the clinical offer to the actual preparation. It identifies the available documentation without interpreting unexplained pharmacy codes, choosing a treatment or treating an advertised delivery process as a completed prescription. Prices and service descriptions remain the provider’s published statements.
In this article
The consultation can result in more than one answer
The menopause service page explicitly says a clinician decides whether estrogen, progesterone or neither belongs in a plan. That establishes relevant clinical care while preserving an important distinction: discussing this hormone is not the same as deciding that a reader needs an oral capsule. The page describes a dedicated clinical visit rather than a simple product purchase.
The medicine-purpose guide helps frame the first question: what job would progesterone have in the proposed treatment? A symptom list or an age group cannot supply that answer alone. A review should retain the possibility that assessment leads to another approach, even when the service advertises hormone therapy prominently.
Capsule listings have details the table does not explain
Thrivelab’s medication table includes progesterone capsule entries, creams, troches and combinations with other named ingredients. It also uses abbreviations such as SR, SB and E4M without providing a complete explanation alongside every entry. Some entries combine progesterone with melatonin and theanine. Those combinations must not be read as progesterone alone.
The table has separate pricing headings dated April 5, 2024 and February 19, 2025. A fresh visit to the page does not make those displayed price dates current. This review does not decode a release mechanism, infer a capsule count or calculate a monthly medicine cost from those entries. Defy Medical’s review considers a different menu whose hormone and delivery lists also require clarification.
Personalized does not identify the approval record
The FAQ describes compounded prescriptions and states that compounded hormone therapy is not FDA approved. FDA’s explanation confirms the relevant limit: a compounded medicine has not undergone the agency’s premarket review for safety, effectiveness and quality. A pharmacy category or a licensed prescriber does not change that approval status.
That does not establish a defect in a particular supplied capsule, which this review has not inspected. It means a proposed preparation needs its own description and a reason for its use. The label for an approved progesterone product cannot simply be attached to a differently prepared combination because one active ingredient has the same name.
A base or shell needs its own ingredient record
The capsule-excipients guide explains why an active ingredient is only part of a medicine’s identity. For a concrete comparison, the FDA Prometrium label identifies peanut oil and gelatin among that product’s ingredients and contraindicates it in people allergic to peanuts. This is product-specific information, not a claim about every Thrivelab capsule.
The public medication list does not establish the complete shell, carrier, colors or other ingredients for an individual order. A pharmacist can identify the actual preparation and explain its ingredient record. Neither plant-derived marketing nor an unexplained code provides enough information to assess an allergy question.
The pages leave different impressions about testing and reach
The service description says testing occurs before prescribing and uses nationwide delivery language. The FAQ says a clinician may begin hormone care without baseline laboratory work and acknowledges that some states may not yet be covered. These are differences in the published descriptions; this review does not silently choose one as the universal rule.
The practical question is what applies to the reader’s location and proposed care. Testing statements describe the service’s process, not a schedule to follow independently. BodyLogicMD’s review provides another example where a testing program and a medication decision need separate explanation.
Separate care payments from the preparation price
The FAQ quotes a general medication range of $80–$140 a month depending on recommendations, rather than a guaranteed oral-progesterone price. Its self-pay description lists $49 a month paid quarterly or $40 a month paid annually, plus $45 per telehealth visit. It separately calls the initial self-pay appointment $94. The relationship between that initial amount and the longer billing commitments needs confirmation.
Insurance verification, diagnostic charges and medicine coverage are also separate questions. The FAQ’s refund wording permits case-by-case clinical-care or appointment refunds while excluding prescriptions and partial Thrively payments. None of those statements makes a capsule order refundable or proves a particular insurer will pay.
Follow-up should explain the medicine rather than just renew it
The service page advertises coordinated refills and plan changes. That convenience still needs a named clinical contact for concerns and a pharmacy contact for ingredient or dispensing questions. The follow-up guide helps distinguish those responsibilities without creating a personal treatment schedule.
The useful outcome of this review is a more specific conversation: identify the prescribed ingredients, route, preparation and reason for use, then clarify the cost and response process. Thrivelab’s records establish a service to ask, but do not verify an individual capsule, treatment result, pharmacy transaction or ongoing supply. No patient account or consultation was used for this assessment.
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- Thrivelab: Menopause hormone careProvider clinical-service description; treatment and access wording is not an individual prescribing or state-eligibility confirmation · Checked 2026-09-29
- Thrivelab: Medication pricesProvider medication tables dated April 5, 2024 and February 19, 2025; current page access does not update historical prices or explain formulation codes · Checked 2026-09-29
- Thrivelab: Frequently asked questionsProvider FAQ; separate membership, medication, state-access, laboratory and refund descriptions retain their stated limits · Checked 2026-09-29
- FDA: Understanding the Risks of Compounded DrugsFederal primary guidance on compounding and lack of FDA premarket approval; not individual treatment advice · Checked 2026-09-29
- FDA: Prometrium progesterone capsules prescribing informationExact FDA product label, reference ID 5744934; ingredients, indications and warnings apply to this product, not all progesterone preparations · Checked 2026-09-29